Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 14, Issue 11, 2008, Pages 1585-1596

  Vanderpool, Charles ^a   Yan, Fang ^a   Polk, D Brent ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immune response; Intestinal epithelial cell; Mechanism; Probiotics; Signaling pathway

Indexed keywords

ACETIC ACID; AZATHIOPRINE; BACTERIOCIN; CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTIC ACID; LANTIBIOTIC; MERCAPTOPURINE; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROBIOTIC AGENT; PROPIONIC ACID; PROTEIN KINASE B; TOLL LIKE RECEPTOR; VSL3;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BACTEROIDES VULGATUS; BIFIDOBACTERIUM; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM INFANTIS; CELL ACTIVATION; CELL FUNCTION; CELL SURVIVAL; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM HISTOLYTICUM; COMPETITIVE INHIBITION; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; EPITHELIUM CELL; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; HUMAN; ILEITIS; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; INTESTINE ANASTOMOSIS; INTESTINE EPITHELIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS SALIVARIUS; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; UPREGULATION; ANIMAL; BACTERIAL INFECTION; FEMALE; IMMUNOLOGY; INTESTINE; INTESTINE MUCOSA; MALE; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANIMALS; BACTERIAL INFECTIONS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES; MALE; PROBIOTICS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 59249100550     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20525     Document Type: Review

References (95)

1. Lilly DM, Stillwell RH. Probiotics: Growth-promoting factors produced by microorganisms. Science. 1965;147:747-748.
2. Walker WA, Goulet O, Morelli L, et al. Progress in the science of probiotics: from cellular microbiology and applied immunology to clinical nutrition. Eur J Nutr. 2006;45:1-18.
3. Yan F, Polk DB. Commensal bacteria in the gut: learning who our friends are. Curr Opin Gastroenterol. 2004;20:565-571.
4. Yan F, Polk DB. Probiotics as functional food in the treatment of diarrhea. Curr Opin Clin Nutr Metab Care. 2006;9:717-721.
5. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114.
6. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-1209.
7. Lammers KM, Vergopoulos A, Babel N, et al. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Inflamm Bowel Dis. 2005;11: 447-454.
8. Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis. 2008;14:662-668.
9. Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17:509-515.
10. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-639.
11. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20:1133-1141.
12. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-1546.
13. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-1623.
14. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1567-1574.
15. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004;4:5.
16. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis. 2005;11:833-839.
17. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55:842-847.
18. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51:405-409.
19. Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 2006; 55:1760-1767.
20. Mylonaki M, Rayment NB, Rampton DS, et al. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:481-487.
21. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685-693.
22. Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev. 2005;3:777-788.
23. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev. 2004;28:405-440.
24. Lawton EM, Ross RP, Hill C, et al. Two-peptide lantibiotics: a medical perspective. Mini Rev Med Chem. 2007;7:1236-1247.
25. Morgan SM, O'Connor PM, Cotter PD, et al. Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Chemother. 2005;49:2606-2611.
26. Cotter PD, Deegan LH, Lawton EM, et al. Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol Microbiol. 2006;62:735-747.
27. Makarova K, Slesarev A, Wolf Y, et al. Comparative genomics of the lactic acid bacteria. Proc Natl Acad Sci U S A. 2006;103:15611-15616.
28. Chaillou S, Champomier-Verges MC, Cornet M, et al. The complete genome sequence of the meat-borne lactic acid bacterium Lactobacillus sakei 23K. Nat Biotechnol. 2005;23:1527-1533.
29. Altermann E, Russell WM, Azcarate-Peril MA, et al. Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc Natl Acad Sci U S A. 2005; 102:3906-3912.
30. Pridmore RD, Berger B, Desiere F, et al. The genome sequence of the probiotic intestinal bacterium Lactobacillus johnsonii NCC 533. Proc Natl Acad Sci U S A. 2004;101:2512-2517.
31. Collado MC, Hernandez M, Sanz Y. Production of bacteriocin-like inhibitory compounds by human fecal Bifidobacterium strains. J Food Prot. 2005;68:1034-1040.
32. Makras L, Triantafyllou V, Fayol-Messaoudi D, et al. Kinetic analysis of the antibacterial activity of probiotic lactobacilli towards Salmonella enterica serovar Typhimurium reveals a role for lactic acid and other inhibitory compounds. Res Microbiol. 2006;157:241-247.
33. De Keersmaecker SC, Verhoeven TL, Desair J, et al. Strong antimicrobial activity of Lactobacillus rhamnosus GG against Salmonella typhimurium is due to accumulation of lactic acid. FEMS Microbiol Lett. 2006;259:89-96.
34. Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol. 2007;45:454-460.
35. Candela M, Seibold G, Vitali B, et al. Real-time PCR quantification of bacterial adhesion to Caco-2 cells: competition between bifidobacteria and enteropathogens. Res Microbiol. 2005;156:887-895.
36. Roselli M, Finamore A, Britti MS, et al. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. Br J Nutr. 2006;95:1177-1184.
37. Sherman PM, Johnson-Henry KC, Yeung HP, et al. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun. 2005;73:5183-5188.
38. Mukai T, Kaneko S, Matsumoto M, et al. Binding of Bifidobacterium bifidum and Lactobacillus reuteri to the carbohydrate moieties of intestinal glycolipids recognized by peanut agglutinin. Int J Food Microbiol. 2004;90:357-362.
39. Sun J, Le GW, Shi YH, et al. Factors involved in binding of Lactobacillus plantarum Lp6 to rat small intestinal mucus. Lett Appl Microbiol. 2007;44:79-85.
40. Tallon R, Arias S, Bressollier P, et al. Strain- and matrix-dependent adhesion of Lactobacillus plantarum is mediated by proteinaceous bacterial compounds. J Appl Microbiol. 2007;102:442-451.
41. Paton AW, Jennings MP, Morona R, et al. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology. 2005;128:1219-1228.
42. Focareta A, Paton JC, Morona R, et al. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology. 2006;130:1688-1695.
43. Kraehenbuhl JP, Corbett M. Immunology. Keeping the gut microflora at bay. Science. 2004;303:1624-1625.
44. Winkler P, Ghadimi D, Schrezenmeir J, et al. Molecular and cellular basis of microflora-host interactions. J Nutr. 2007;137:756S-772S.
45. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004;303:1662-1665.
46. Bakker-Zierikzee AM, Tol EA, Kroes H, et al. Faecal SIgA secretion in infants fed on pre- or probiotic infant formula. Pediatr Allergy Immunol. 2006;17:134-140.
47. He F, Morita H, Kubota A, et al. Effect of orally administered non-viable Lactobacillus cells on murine humoral immune responses. Microbiol Immunol. 2005;49:993-997.
48. Veckman V, Miettinen M, Pirhonen J, et al. Streptococcus pyogenes and Lactobacillus rhamnosus differentially induce maturation and production of Th1-type cytokines and chemokines in human monocyte-derived dendritic cells. J Leukoc Biol. 2004;75:764-771.
49. Braat H, de Jong EC, van den Brande JM, et al. Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function. J Mol Med. 2004;82:197-205.
50. Drakes M, Blanchard T, Czinn S. Bacterial probiotic modulation of dendritic cells. Infect Immun. 2004;72:3299-3309.
51. Hart AL, Lammers K, Brigidi P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53:1602-1609.
52. Smits HH, Engering A, van der Kleij D, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005;115:1260-1267.
53. Pena JA, Rogers AB, Ge Z, et al. Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. Infect Immun. 2005;73:912-920.
54. Sheil B, MacSharry J, O'Callaghan L, et al. Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. Clin Exp Immunol. 2006;144:273-280.
55. Pena JA, Versalovic J. Lactobacillus rhamnosus GG decreases TNF-α production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol. 2003;5:277-285.
56. Kim SO, Sheikh HI, Ha SD, et al. G-CSF-mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus-induced suppression of TNF production in macrophages. Cell Microbiol. 2006;8:1958-1971.
57. Matsumoto S, Hara T, Hori T, et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol. 2005;140:417-426.
58. Sturm A, Rilling K, Baumgart DC, et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun. 2005;73:1452-1465.
59. Mazmanian SK, Liu CH, Tzianabos AO, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122:107-118.
60. Mohamadzadeh M, Olson S, Kalina WV, et al. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci U S A. 2005;102:2880-2885.
61. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology. 2004;126:1358-1373.
62. Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nat Med. 2003;9:831-835.
63. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520-528.
64. Cario E, Podolsky DK. Toll-like receptor signaling and its relevance to intestinal in.ammation. Ann N Y Acad Sci. 2006;1072:332-338.
65. Grabig A, Paclik D, Guzy C, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun. 2006;74:4075-4082.
66. Lee J, Mo JH, Katakura K, et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol. 2006;8:1327-1336.
67. Hajjar AM, Ernst RK, Tsai JH, et al. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol. 2002;3:354-359.
68. van Heel DA, Ghosh S, Butler M, et al. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol. 2005; 35:2471-2476.
69. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514-521.
70. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
71. Zyrek AA, Cichon C, Helms S, et al. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol. 2007;9:804-816.
72. Seth A, Yan F, Polk DB, et al. Probiotics ameliorate hydrogen peroxide-induced epithelial barrier disruption by PKC and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1060-G1069.
73. Parassol N, Freitas M, Thoreux K, et al. Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res Microbiol. 2005;156:256-262.
74. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol. 2004;286:G613-626.
75. Resta-Lenert S, Barrett KE. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroenterology. 2006;130:731-746.
76. Tao Y, Drabik KA, Waypa TS, et al. Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol Cell Physiol. 2006;290:C1018-1030.
77. Wehkamp J, Harder J, Wehkamp K, et al. NF-κB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun. 2004;72:5750-5758.
78. Schlee M, Wehkamp J, Altenhoefer A, et al. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun. 2007;75:2399-2407.
79. Schlee M, Harder J, Koten B, et al. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol. 2008;151:528-535.
80. Hooper LV, Stappenbeck TS, Hong CV, et al. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol. 2003;4:269-273.
81. Sartor RB. Mucosal immunology and mechanisms of gastrointestinal in.ammation. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 7th ed. Philadelphia: WB Saunders; 2002:21-51.
82. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem. 2002;277:50959-50965.
83. Yan F, Cao H, Cover TL, et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology. 2007;132:562-575.
84. Zaph C, Troy AE, Taylor BC, et al. Epithelial-cell-intrinsic IKK-b expression regulates intestinal immune homeostasis. Nature. 2007;446: 552-556.
85. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446:557-561.
86. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229-241.
87. Cario E, Brown D, McKee M, et al. Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium. Am J Pathol. 2002;160:165-173.
88. Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin- 8 expression. Infect Immun. 2004;72:5308-5314.
89. O'Hara AM, O'Regan P, Fanning A, et al. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology. 2006;118:202-215.
90. Zhang L, Li N, Caicedo R, et al. Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr. 2005;135:1752-1756.
91. Tien MT, Girardin SE, Regnault B, et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol. 2006;176:1228-1237.
92. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate in.ammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA. Nat Immunol. 2004;5:104-112.
93. Are A, Aronsson L, Wang S, et al. Enterococcus faecalis from newborn babies regulate endogenous PPAR-γ activity and IL-10 levels in colonic epithelial cells. Proc Natl Acad Sci U S A. 2008;105:1943-1948.
94. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651-659.
95. Ridwan BU, Koning CJ, Besselink MG, et al. Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis. Lett Appl Microbiol. 2008;46:61-67.